Fibulin-3-mediated inhibition of epithelial-to-mesenchymal transition and self-renewal of ALDH+ lung cancer stem cells through IGF1R signaling

Oncogene

Volumn 33, Issue 30, 2014, Pages 3908-3917

  Kim, I G ^a,b   Kim, S Y ^a   Choi, S I ^a,b   Lee, J H ^a,b   Kim, K C ^a   Cho, E W ^c  

^a Korea Atomic Energy Research Institute   (South Korea)

^b University of Science and Technology (UST)   (South Korea)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; BETA CATENIN; FIBULIN; FIBULIN 3; GLYCOGEN SYNTHASE KINASE 3BETA; NERVE CELL ADHESION MOLECULE; OCTAMER TRANSCRIPTION FACTOR 4; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR ZEB1; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CELL INVASION; CELL MIGRATION; CELL RENEWAL; CELL STRUCTURE; CELL SUBPOPULATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SPINDLE CELL; TUMOR INVASION;

ADENOCARCINOMA; ALDEHYDE DEHYDROGENASE; ANIMALS; BETA CATENIN; CELL LINE, TUMOR; CELL PROLIFERATION; CHO CELLS; CRICETINAE; CRICETULUS; EPITHELIAL-MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; TUMOR BURDEN;

EID: 84904988112     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.373     Document Type: Article

References (53)

1. Esposito L, Conti D, Ailavajhala R, Khalil N, Giordano A. Lung cancer: Are we up to the challenge?. Curr Genomics 2010; 11: 513-518
2. Heist RS, Christiani D. EGFR-Targeted therapies in lung cancer: Predictors of response and toxicity. Pharmacogenomics 2009; 10: 59-68
3. Alison MR, Lin WR, Lim SM, Nicholson LJ. Cancer stem cells: In the line of fire. Cancer Treat Rev 2012; 38: 589-598
4. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al. The epithelialmesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715 (Pubitemid 351636299)
5. Rivera C, Rivera S, Loriot Y, Vozenin MC, Deutsch E. Lung cancer stem cell: New insights on experimental models and preclinical data. J Oncol 2011; 2011: 549181
6. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737 (Pubitemid 27298715)
7. Korkaya H, Wicha MS. Selective targeting of cancer stem cells: A new concept in cancer therapeutics. BioDrugs 2007; 21: 299-310 (Pubitemid 47529469)
8. Perona R, Lopez-Ayllon BD, de Castro Carpeno J, Belda-Iniesta C. A role for cancer stem cells in Drug resistance and metastasis in non-small-cell lung cancer. Clin Transl Oncol 2011; 13: 289-293
9. Li J, Zhou BP. Activation of beta-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters. BMC Cancer 2011; 11: 49
10. de Vega S, Iwamoto T, Yamada Y. Fibulins: Multiple roles in matrix structures and tissue functions. Cell Mol Life Sci 2009; 66: 1890-1902
11. Schiemann WP, Blobe GC, Kalume DE, Pandey A, Lodish HF. Context-specific effects of fibulin-5 (DANCE/EVEC) on cell proliferation, motility, and invasion. Fibulin-5 is induced by transforming growth factor-beta and affects protein kinase cascades. J Biol Chem 2002; 277: 27367-27377 (Pubitemid 34951757)
12. Yue W, Sun Q, Landreneau R, Wu C, Siegfried JM, Yu J et al. Fibulin-5 suppresses lung cancer invasion by inhibiting matrix metalloproteinase-7 expression. Cancer Res 2009; 69: 6339-6346
13. Hu B, Thirtamara-Rajamani KK, Sim H, Viapiano MS. Fibulin-3 is uniquely upregulated in malignant gliomas and promotes tumor cell motility and invasion. Mol Cancer Res 2009; 7: 1756-1770
14. Hu Y, Pioli PD, Siegel E, Zhang Q, Nelson J, Chaturbedi A et al. EFEMP1 suppresses malignant glioma growth and exerts its action within the tumor extracellular compartment. Mol Cancer 2011; 10: 123
15. Kim EJ, Lee SY, Woo MK, Choi SI, Kim TR, Kim MJ et al. Fibulin-3 promoter methylation alters the invasive behavior of non-small cell lung cancer cell lines via MMP-7 and MMP-2 regulation. Int J Oncol 2012; 40: 402-408
16. Sung JM, Cho HJ, Yi H, Lee CH, Kim HS, Kim DK et al. Characterization of a stem cell population in lung cancer A549 cells. Biochem Biophys Res Commun 2008; 371: 163-167
17. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in Development and disease. Cell 2009; 139: 871-890
18. Araki K, Shimura T, Suzuki H, Tsutsumi S, Wada W, Yajima T et al. E/N-cadherin switch mediates cancer progression via TGF-beta-induced epithelial-Tomesenchymal transition in extrahepatic cholangiocarcinoma. Br J Cancer 2011; 105: 1885-1893
19. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: New insights in signaling, development, and disease. J Cell Biol 2006; 172: 973-981
20. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A et al. The EMTactivator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009; 11: 1487-1495
21. Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi JP, Nevo J, Gjerdrum C et al. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene 2011; 30: 1436-1448
22. Biddle A, Mackenzie IC. Cancer stem cells and EMT in carcinoma. Cancer Metastasis Rev 2012; 31: 285-293
23. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than Do serum-cultured cell lines. Cancer Cell 2006; 9: 391-403 (Pubitemid 43668737)
24. Pastrana E, Silva-Vargas V, Doetsch F. Eyes wide open: A critical review of sphereformation as an assay for stem cells. Cell Stem Cell 2011; 8: 486-498
25. OBrien CA, Kreso A, Jamieson CH. Cancer stem cells and self-renewal. Clin Cancer Res 2010; 16: 3113-3120
26. Fuxe J, Vincent T, Garcia de Herreros A. Transcriptional crosstalk between TGF-beta and stem cell pathways in tumor cell invasion: Role of EMT promoting Smad complexes. Cell Cycle 2010; 9: 2363-2374
27. Jiang YG, Luo Y, He DL, Li X, Zhang LL, Peng T et al. Role of Wnt/beta-catenin signaling pathway in epithelial-mesenchymal transition of human prostate cancer induced by hypoxia-inducible factor-1alpha. Int J Urol 2007; 14: 1034-1039 (Pubitemid 47621827)
28. Hwang CF, Chien CY, Huang SC, Yin YF, Huang CC, Fang FM et al. Fibulin-3 is associated with tumour progression and a poor prognosis in nasopharyngeal carcinomas and inhibits cell migration and invasion via suppressed AKT activity. J Pathol 2010; 222: 367-379
29. Mitsiades CS, Mitsiades N, Koutsilieris M. The Akt pathway: Molecular targets for anti-cancer drug development. Curr Cancer Drug Targets 2004; 4: 235-256 (Pubitemid 38560073)
30. Desbois-Mouthon C, Cadoret A, Blivet-Van Eggelpoel MJ, Bertrand F, Cherqui G, Perret C et al. Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. Oncogene 2001; 20: 252-259 (Pubitemid 32150270)
31. Doble BW, Woodgett JR. Role of glycogen synthase kinase-3 in cell fate and epithelial-mesenchymal transitions. Cells Tissues Organs 2007; 185: 73-84 (Pubitemid 46956846)
32. Cappuzzo F, Tallini G, Finocchiaro G, Wilson RS, Ligorio C, Giordano L et al. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. Ann Oncol 2010; 21: 562-567
33. Engelman JA, Janne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA 2005; 102: 3788-3793 (Pubitemid 40354690)
34. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001; 61: 3986-3997 (Pubitemid 32720961)
35. Morrison R, Schleicher SM, Sun Y, Niermann KJ, Kim S, Spratt DE et al. Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. J Oncol 2011; 2011: 941876
36. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1: 555-567 (Pubitemid 350056407)
37. Ucar D, Cogle CR, Zucali JR, Ostmark B, Scott EW, Zori R et al. Aldehyde dehydrogenase activity as a functional marker for lung cancer. Chem Biol Interact 2009; 178: 48-55
38. Jiang T, Collins BJ, Jin N, Watkins DN, Brock MV, Matsui W et al. Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer. Cancer Res 2009; 69: 845-854
39. Ischenko I, Seeliger H, Schaffer M, Jauch KW, Bruns CJ. Cancer stem cells: How can we target them?. Curr Med Chem 2008; 15: 3171-3184
40. Gorelik E, Lokshin A, Levina V. Lung cancer stem cells as a target for therapy. Anticancer Agents Med Chem 2010; 10: 164-171
41. McCubrey JA, Steelman LS, Abrams SL, Misaghian N, Chappell WH, Basecke J et al. Targeting the cancer initiating cell: The ultimate target for cancer therapy. Curr Pharm Des 2012; 18: 1784-1795
42. Prudhomme GJ. Cancer stem cells and novel targets for antitumor strategies. Curr Pharm Des 2012; 18: 2838-2849
43. Hu B, Nandhu MS, Sim H, Agudelo-Garcia PA, Saldivar JC, Dolan CE et al. Fibulin-3 promotes glioma growth and resistance through a novel paracrine regulation of Notch signaling. Cancer Res 2012; 72: 3873-3885
44. Camaj P, Seeliger H, Ischenko I, Krebs S, Blum H, De Toni EN et al. EFEMP1 binds the EGF receptor and activates MAPK and Akt pathways in pancreatic carcinoma cells. Biol Chem 2009; 390: 1293-1302
45. Wang R, Zhang YW, Chen LB. Aberrant promoter methylation of FBLN3 gene and clinicopathological significance in non-small cell lung carcinoma. Lung Cancer 2010; 69: 239-244
46. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915-928
47. Yang J, Ylipaa A, Sun Y, Zheng H, Chen K, Nykter M et al. Genomic and molecular characterization of malignant peripheral nerve sheath tumor identifies the IGF1R pathway as a primary target for treatment. Clin Cancer Res 2011; 17: 7563-7573
48. Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA, Lemischka IR. A stem cell molecular signature. Science 2002; 298: 601-604
49. Bendall SC, Stewart MH, Menendez P, George D, Vijayaragavan K, Werbowetski-Ogilvie T et al. IGF and FGF cooperatively establish the regulatory stem cell niche of pluripotent human cells in vitro. Nature 2007; 448: 1015-1021 (Pubitemid 47345578)
50. Jones RA, Campbell CI, Wood GA, Petrik JJ, Moorehead RA. Reversibility and recurrence of IGF-IR-induced mammary tumors. Oncogene 2009; 28: 2152-2162
51. Shan J, Shen J, Liu L, Xia F, Xu C, Duan G et al. Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Hepatology 2012; 56: 1004-1014
52. Bill A, Schmitz A, Konig K, Heukamp LC, Hannam JS, Famulok M. Anti-proliferative effect of cytohesin inhibition in gefitinib-resistant lung cancer cells. PloS One 2012; 7: E41179
53. Desbois-Mouthon C, Baron A, Blivet-Van Eggelpoel MJ, Fartoux L, Venot C, Bladt F et al. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: Rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Clin Cancer Res 2009; 15: 5445-5456.